11
Aug
2022

Karuna’s Schizophrenia Advance, FDA Clears HER2-Low Drug, & Pfizer Buys GBT

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Merck Bets $10B on COPD, AbbVie Buys In Vivo CAR-T, & FDA Transparency
Avidity Advances in FSHD, Insmed Passes PAH Test, Merck Delivers with Oral PCSK9
Sanofi Buys Blueprint, BMS Antes for BioNTech Bispecific, & Kymera Degrader Delivers
GSK Antibiotic Hits, ORIC Prostate Cancer Drug Shines, & Taysha Goes 10-for-10